AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34921836 — intervention group
Group type: COMPARATOR
Intervention: Routine care (CON)
Number of subjects: 57
Study 34207661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reduce sitting time
Number of subjects: 84
Study 34207661 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 35175971 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free on the Web (PSFW+); N = 255
Number of subjects: 506
Study 35175971 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association Getting Healthy (control); N = 251
Number of subjects: 506
Study 33706032 — intervention group
Group type: EXPERIMENTAL
Intervention: TB treatment support tools (TB‐TSTs)
Number of subjects: 42
Study 35617330 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCP team intervention
Number of subjects: 26
Study 34222086 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylethylpiridinol addition to therapy
Number of subjects: 0
Study 32645767 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 24
Study 32645767 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 32645767 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH
Number of subjects: 24
Study 33032893 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient initiation of sacubitril/valsartan
Number of subjects: 840
Study 33032893 — intervention group
Group type: COMPARATOR
Intervention: Outpatient initiation of sacubitril/valsartan
Number of subjects: 840
Study 33626929 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy and local therapy (radiation, surgery, thermal ablation)
Number of subjects: 102
Study 33626929 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 102
Study 33213815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 113
Study 33213815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 35635687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate (LXB)
Number of subjects: 4
Study 32732442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-loop group (30 patients)
Number of subjects: 60
Study 32732442 — intervention group
Group type: COMPARATOR
Intervention: Adjustable-loop group (30 patients)
Number of subjects: 60
Study 35251416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 ml infiltration injection)
Number of subjects: 80
Study 35251416 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 ml infiltration injection)
Number of subjects: 80
Study 33710131 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBN Preservation
Number of subjects: 48
Study 33710131 — intervention group
Group type: COMPARATOR
Intervention: ICBN Sacrifice
Number of subjects: 48
Study 32266366 — intervention group
Group type: EXPERIMENTAL
Intervention: Franchised gyms
Number of subjects: 90
Study 32266366 — intervention group
Group type: COMPARATOR
Intervention: Gyms without swimming pools
Number of subjects: 90
Study 35433565 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Module on Hand, Food, and Mouth Diseases
Number of subjects: 86
Study 35433565 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 34281377 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 443
Study 34281377 — intervention group
Group type: COMPARATOR
Intervention: Control arm (intravenous alteplase)
Number of subjects: 443
Study 34281377 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 443
Study 34907038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociological variety indicators (e.g., crowding, movement, livelihoods, recreational activity)
Number of subjects: 15
Study 34907038 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially open communities with poor ventilation (e.g., watching video shows)
Number of subjects: 15
Study 34907038 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor farming and/or fishing in communities with lower transmission measures
Number of subjects: 15
Study 34907038 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustments to socio-spatial aspects (e.g., increasing ventilation on transport)
Number of subjects: 15
Study 34907038 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of community level typologies with genome sequencing techniques
Number of subjects: 15
Study 33338662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium nitrite (15 mg twice daily)
Number of subjects: 30
Study 33338662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35512458 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF 320/14.4/10 μg
Number of subjects: 8509
Study 35512458 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF 160/14.4/10 μg
Number of subjects: 8509
Study 35512458 — intervention group
Group type: COMPARATOR
Intervention: GFF 14.4/10 μg
Number of subjects: 8509
Study 35512458 — intervention group
Group type: COMPARATOR
Intervention: BFF 320/10 μg
Number of subjects: 8509
Study 33268020 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0
Study 33268020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (LZP)
Number of subjects: 0
Study 33268020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35231098 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐CircuiT (46 min/session, three supervised sessions/week for 3 months)
Number of subjects: 48
Study 35231098 — intervention group
Group type: COMPARATOR
Intervention: Control (1-time advice on physical activity without supervised exercise)
Number of subjects: 48
Study 35231098 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐CircuiT
Number of subjects: 48
Study 35231098 — intervention group
Group type: COMPARATOR
Intervention: X‐CircuiT vs Control
Number of subjects: 48
Study 32563277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib plus gefitinib
Number of subjects: 55
Study 32563277 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 55
Study 34963006 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2 (SB)
Number of subjects: 35
Study 34963006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambar (AM)
Number of subjects: 35
Study 33950583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (WHO STOPS Childhood Obesity)
Number of subjects: 1792
Study 35442219 — intervention group
Group type: EXPERIMENTAL
Intervention: Healer-delivered HIV testing
Number of subjects: 107
Study 33270487 — intervention group
Group type: EXPERIMENTAL
Intervention: Men-AC vaccine
Number of subjects: 0
Study 33270487 — intervention group
Group type: COMPARATOR
Intervention: Lanzhou-AC vaccine (Control)
Number of subjects: 0
Study 33919758 — intervention group
Group type: EXPERIMENTAL
Intervention: INTER-ACT lifestyle intervention (smartphone application + 4 face-to-face coaching sessions between 6 weeks and 6 months postpartum)
Number of subjects: 0
Study 33919758 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36004504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BTX‐A injection (50‐65 U)
Number of subjects: 49
Study 36004504 — intervention group
Group type: COMPARATOR
Intervention: Intradermal normal saline (NS) injection
Number of subjects: 49
Study 36279088 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic drain placement
Number of subjects: 108
Study 36279088 — intervention group
Group type: COMPARATOR
Intervention: No drain placement
Number of subjects: 108
Study 33022345 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 52
Study 33022345 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 52
Study 35249225 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT; 70% maximal heart rate, 45 min; n=17)
Number of subjects: 36
Study 35249225 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT; 90% maximal heart rate, 10×1 min; n=19)
Number of subjects: 36
Study 33838349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 12 μg BID
Number of subjects: 606
Study 33838349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 μg BID
Number of subjects: 606
Study 33838349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 32245464 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 20 mg/day for 4 weeks, then 10 mg/day for 8 weeks after left hip fracture surgery.
Number of subjects: 1
Study 32245464 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 20 mg/day started at fracture occurrence, continued for 4 weeks, then reduced to 10 mg/day for 8 weeks after right hip fracture surgery.
Number of subjects: 1
Study 35898773 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen injection combined with magnesium sulfate
Number of subjects: 60
Study 35898773 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (control)
Number of subjects: 60
Study 33904664 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of Mountain Dew® (caffeinated soft drink sweetened with high-fructose corn syrup)
Number of subjects: 14
Study 33904664 — intervention group
Group type: COMPARATOR
Intervention: 500 ml of tap water (H2O)
Number of subjects: 14
Study 32452969 — intervention group
Group type: EXPERIMENTAL
Intervention: Male condom with placebo silicone vaginal ring
Number of subjects: 70
Study 32452969 — intervention group
Group type: COMPARATOR
Intervention: Male condom without placebo silicone vaginal ring
Number of subjects: 70
Study 36378553 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1 g/day; 1.2:1 ratio of eicosapentaenoic to docosahexaenoic acid)
Number of subjects: 25871
Study 34116708 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site pharmacists integrated into healthcare teams for 2 to 2.5 days per week for 12 months
Number of subjects: 1188
Study 34116708 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1188
Study 34116708 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site pharmacists integrated into healthcare teams
Number of subjects: 1188
Study 32956433 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term water storage
Number of subjects: 50
Study 32956433 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal degradation with autoclaving
Number of subjects: 50
Study 32956433 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical degradation with hydrochloric acid
Number of subjects: 50
Study 32956433 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical degradation with citric acid
Number of subjects: 50
Study 32956433 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study 34951021 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium indicus pranii (MIP)
Number of subjects: 315
Study 34951021 — intervention group
Group type: COMPARATOR
Intervention: Best standard treatment (BST)
Number of subjects: 315
Study 34795952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin (clinical dose) added to conventional therapy (non-steroidal anti-inflammatory drugs and/or acetaminophen) for 8 weeks
Number of subjects: 0
Study 34795952 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (non-steroidal anti-inflammatory drugs and/or acetaminophen) without mirogabalin
Number of subjects: 0
Study 34795952 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without mirogabalin)
Number of subjects: 0
Study 32725772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin dose per kilogram lean body mass (LBM) in the first course
Number of subjects: 157
Study 32725772 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (concurrent platinum–etoposide chemotherapy and thoracic radiotherapy)
Number of subjects: 157
Study 34906334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg daily) with FLAG-IDA (fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor)
Number of subjects: 17
Study 34906334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg daily) with FLAG-IDA
Number of subjects: 17
Study 35002919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive telerehabilitation through HomeCoRe
Number of subjects: 40
Study 35002919 — intervention group
Group type: COMPARATOR
Intervention: In-person cognitive intervention through CoRe
Number of subjects: 40
Study 35084987 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (3 cycles of gemcitabine + 36 Gy radiotherapy in 15 fractions) followed by surgery and 4 cycles of adjuvant gemcitabine
Number of subjects: 246
Study 35084987 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery followed by 6 cycles of adjuvant gemcitabine
Number of subjects: 246
Study 33063439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 527
Study 33091752 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) supplementation at 150 mg/kg/d for 12 weeks
Number of subjects: 24
Study 33091752 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric and isonitrogenic breeder diet (Control, LC-0)
Number of subjects: 24
Study 35569569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral motor intervention combined with non-nutritive sucking
Number of subjects: 60
Study 35569569 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive sucking intervention alone
Number of subjects: 60
Study 34018981 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 50
Study 34018981 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 50
Study 34018981 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study 32385016 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing alongside conventional nursing care
Number of subjects: 60
Study 32385016 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 60
Study 36147329 — intervention group
Group type: EXPERIMENTAL
Intervention: BRII-196 (up to 3000 mg)
Number of subjects: 44
Study 36147329 — intervention group
Group type: EXPERIMENTAL
Intervention: BRII-198 (up to 3000 mg)
Number of subjects: 44
Study 36147329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BRII-196 and BRII-198 (up to 1500/1500 mg)
Number of subjects: 44
Study 36147329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 36147329 — intervention group
Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Number of subjects: 44
Study 33356011 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (1 mg/day for 1 week)
Number of subjects: 51
Study 34856379 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-guided dry-weight reduction (n = 35)
Number of subjects: 71
Study 34856379 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment (n = 36)
Number of subjects: 71
Study 34856379 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-guided dry-weight reduction
Number of subjects: 71
Study 34856379 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 71
Study 32167568 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 73
Study 32167568 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 73
Study 33384915 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure intervention delivered by school staff (two 90-minute group sessions incorporating cognitive-behavioural therapy and motivational interviewing)
Number of subjects: 12
Study 33384915 — intervention group
Group type: COMPARATOR
Intervention: Usual Health Education curriculum (control condition)
Number of subjects: 12
Study 32179568 — intervention group
Group type: EXPERIMENTAL
Intervention: oat-RUTF
Number of subjects: 1406
Study 32179568 — intervention group
Group type: COMPARATOR
Intervention: s-RUTF
Number of subjects: 1406
Study 34119421 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g flaxseed supplementation
Number of subjects: 112
Study 34119421 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g flaxseed supplementation
Number of subjects: 112
Study 34119421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 34906295 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 knockdown (si-PCSK9)
Number of subjects: 0
Study 34906295 — intervention group
Group type: COMPARATOR
Intervention: Negative control small interfering RNA (si-NC)
Number of subjects: 0
Study 34906295 — intervention group
Group type: COMPARATOR
Intervention: EndoMT group (no treatment)
Number of subjects: 0
Study 34906295 — intervention group
Group type: COMPARATOR
Intervention: Blank group (no treatment)
Number of subjects: 0
Study 33792496 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) in addition to conventional physiotherapy rehabilitation program (CPRP) for 8 weeks
Number of subjects: 30
Study 33792496 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy rehabilitation program (CPRP) that included balance exercises
Number of subjects: 30
Study 34565678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedinvetmab (0.5–1.0 mg kg–1, n = 141)
Number of subjects: 287
Study 34565678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, n = 146)
Number of subjects: 287
Study 34565678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedinvetmab (0.5–1.0 mg kg–1)
Number of subjects: 287
Study 32455620 — intervention group
Group type: EXPERIMENTAL
Intervention: DieTBra
Number of subjects: 111
Study 32455620 — intervention group
Group type: EXPERIMENTAL
Intervention: DieTBra + EVOO (52 mL/day)
Number of subjects: 111
Study 32455620 — intervention group
Group type: COMPARATOR
Intervention: EVOO (52 mL/day)
Number of subjects: 111
Study 36382849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat 25 mg/m2
Number of subjects: 44
Study 36382849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat 50 mg/m2
Number of subjects: 44
Study 36382849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Number of subjects: 44
Study 32975708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus epirubicin (NE)
Number of subjects: 91
Study 32975708 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus epirubicin (PE)
Number of subjects: 91
Study 32613209 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival grafts (FGGs)
Number of subjects: 28
Study 32613209 — intervention group
Group type: COMPARATOR
Intervention: Mucosal excision
Number of subjects: 28
Study 35619119 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 40
Study 34066720 — intervention group
Group type: EXPERIMENTAL
Intervention: Active School Travel (AST) promotion through behaviour change frameworks
Number of subjects: 145
Study 32546249 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational level
Number of subjects: 244
Study 32546249 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 244
Study 32546249 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level and residence zone interaction
Number of subjects: 244
Study 35353352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 35353352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34044563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mL
Number of subjects: 60
Study 34044563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mL
Number of subjects: 60
Study 34044563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 30 mL
Number of subjects: 60
Study 35131096 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. olcegepant (n=8)
Number of subjects: 16
Study 35131096 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (n=8)
Number of subjects: 16
Study 35123662 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (anastrozole, exemestane, or letrozole)
Number of subjects: 7030
Study 35123662 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 7030
Study 32782219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based radiomic nomogram
Number of subjects: 886
Study 32782219 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic nomogram
Number of subjects: 886
Study 36413167 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed model preoperative planning
Number of subjects: 20
Study 36413167 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative planning
Number of subjects: 20
Study 36008554 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling HPV test
Number of subjects: 7340
Study 34020886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cooling (CWI: 30 min of cold water immersion at 22 °C)
Number of subjects: 9
Study 34020886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cooling combined with per-cooling (PRE + PER)
Number of subjects: 9
Study 34020886 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up per-cooling (PER: neck-cooling collar applied during the preload)
Number of subjects: 9
Study 34020886 — intervention group
Group type: COMPARATOR
Intervention: No-cooling (CON)
Number of subjects: 9
Study 32820083 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD (FEV1/FVC <0.70)
Number of subjects: 108246
Study 32820083 — intervention group
Group type: EXPERIMENTAL
Intervention: GLI (FEV1/FVC <LLN)
Number of subjects: 108246
Study 32820083 — intervention group
Group type: EXPERIMENTAL
Intervention: NHANES (FEV1/FVC <LLN)
Number of subjects: 108246
Study 32820083 — intervention group
Group type: EXPERIMENTAL
Intervention: ECSC (FEV1/FVC <LLN)
Number of subjects: 108246
Study 32820083 — intervention group
Group type: EXPERIMENTAL
Intervention: CCHS/CGPS (FEV1/FVC <LLN)
Number of subjects: 108246
Study 34854538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 49) where the treating team was provided with a summary of family psychosocial risk, measured by the Psychosocial Assessment Tool (PAT)
Number of subjects: 93